Literature DB >> 2526329

Absorption of 5'-deoxy-5-fluorouridine from colon.

J L Au1, L C Gunnarsson.   

Abstract

Rectally administered 5'-deoxy-5-fluorouridine (dFUR) is active against transplanted dimethylhydrazine-induced colon tumor in rats. This study investigated the disposition of dFUR in normal non-tumor-bearing rats after rectal administration (350 or 700 mg/kg). An intravenous (iv) bolus injection of [5'-3H]dFUR (28.2 muCi, 0.43 micrograms) was given 5 min after the rectal dose (700 mg/kg) to determine the dFUR clearance (CL). Blood and fecal samples were analyzed by high-pressure liquid chromatography and liquid scintillation. After the iv tracer dose, the CL was 19 ml/min/kg and the terminal half-life was 50 min. After a 700-mg/kg rectal dose, the terminal half-life was 430 min, the bioavailability was 30%, and the fraction of the dose recovered in 24-hr feces was 34%. After a 350-mg/kg dose, absorption was apparently not completed at 12 hr, as indicated by a lack of decline in blood concentration. The bioavailability of the 350-mg/kg dose exceeded 16%. The absorption of dFUR (700 mg/kg) from the colon was analyzed by the Loo-Riegelman method: the absorption half-life was 550 min. The terminal half-life after the rectal dose was much slower than that after the iv tracer dose but similar to the absorption half-life. These data indicate that dFUR was absorbed from the colon, that the absorption process was the rate-limiting step of its disposition after rectal administration, and that the slow absorption gave a sustained drug concentration in blood.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2526329     DOI: 10.1023/a:1015902625456

Source DB:  PubMed          Journal:  Pharm Res        ISSN: 0724-8741            Impact factor:   4.200


  9 in total

1.  New method for calculating the intrinsic absorption rate of drugs.

Authors:  J C Loo; S Riegelman
Journal:  J Pharm Sci       Date:  1968-06       Impact factor: 3.534

2.  Noncompartmental determination of the steady-state volume of distribution.

Authors:  L Z Benet; R L Galeazzi
Journal:  J Pharm Sci       Date:  1979-08       Impact factor: 3.534

3.  Disposition and availability of 5-fluorouracil prodrug 5'-deoxy-5-fluorouridine after oral administration in rats.

Authors:  J L Au
Journal:  J Pharm Sci       Date:  1987-09       Impact factor: 3.534

4.  Phase II study of 5'-deoxy-5-fluorouridine (doxifluridine) in advanced malignant melanoma.

Authors:  P Alberto; M Rozencweig; M Clavel; P Siegenthaler; F Cavalli; S Gundersen; U Bruntsch; J Renard; H Pinedo
Journal:  Cancer Chemother Pharmacol       Date:  1986       Impact factor: 3.333

5.  Pharmacokinetic studies of 5-fluorouracil and 5'-deoxy-5-fluorouridine in rats.

Authors:  J L Au; J S Walker; Y Rustum
Journal:  J Pharmacol Exp Ther       Date:  1983-10       Impact factor: 4.030

6.  Avoidance of "first-pass" elimination of rectally administered lidocaine in relation to the site of absorption in rats.

Authors:  L G de Leede; A G de Boer; C P Roozen; D D Breimer
Journal:  J Pharmacol Exp Ther       Date:  1983-04       Impact factor: 4.030

7.  Rectal absorption of nitroglycerin in the rat: avoidance of first-pass metabolism as a function of rectal length exposure.

Authors:  A Kamiya; H Ogata; H L Fung
Journal:  J Pharm Sci       Date:  1982-06       Impact factor: 3.534

8.  Biologic activity of 5'-deoxy-5-fluorouridine by rectal administration.

Authors:  S L Bramer; L C Gunnarsson; J L Au
Journal:  Pharm Res       Date:  1989-04       Impact factor: 4.200

9.  Cellular basis for the inefficacy of 5-FU in human colon carcinoma.

Authors:  B Drewinko; L Y Yang
Journal:  Cancer Treat Rep       Date:  1985-12
  9 in total
  1 in total

1.  Biologic activity of 5'-deoxy-5-fluorouridine by rectal administration.

Authors:  S L Bramer; L C Gunnarsson; J L Au
Journal:  Pharm Res       Date:  1989-04       Impact factor: 4.200

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.